A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive^TM) for COVID-19 Patients

Table 6

COVID-19 quality of life questionnaire.

Parameter	Active (ImmuActive^TM) group (N = 45)	Placebo (microcrystalline cellulose) group (N = 47)	value
Screening visit (visit 1)
Mean ± SD	9.51 ± 3.25	9.06 ± 2.98	0.4903 (NS)
Minimum	6.00	6.00
Maximum	23.00	21.00
End visit
Mean ± SD	6.82 ± 1.79	6.83 ± 1.30	0.9757 (NS)
Minimum	6.00	6.00
Maximum	17.00	11.00
Mean change from baseline	−2.69	−2.24
value	<0.0001	<0.0001

NS, not significant; statistically significant.